Haploidentical Hematopoietic Stem Cell Transplantation With Early ATG and Low Dose Post-transplant Cyclophosphamide
Condition: Haploidentical Hematopoietic Stem Cell Transplantation Intervention: Drug: ATG-LDPTCy Sponsor: Samsung Medical Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 18, 2023 Category: Research Source Type: clinical trials
Safety and Efficacy Evaluation of Autologous CRISPR-Cas12b Edited Hematopoietic Stem Cells
Conditions: Thalassemia, Beta; Thalassemia Major Intervention: Biological: VGB-Ex01 Sponsors: Institute of Hematology& Blood Diseases Hospital, China; Shanghai Vitalgen BioPharma Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 18, 2023 Category: Research Source Type: clinical trials
Haploidentical Hematopoietic Stem Cell Transplantation With Early ATG and Low Dose Post-transplant Cyclophosphamide
Condition: Haploidentical Hematopoietic Stem Cell Transplantation Intervention: Drug: ATG-LDPTCy Sponsor: Samsung Medical Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 18, 2023 Category: Research Source Type: clinical trials
Safety and Efficacy Evaluation of Autologous CRISPR-Cas12b Edited Hematopoietic Stem Cells
Conditions: Thalassemia, Beta; Thalassemia Major Intervention: Biological: VGB-Ex01 Sponsors: Institute of Hematology& Blood Diseases Hospital, China; Shanghai Vitalgen BioPharma Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 18, 2023 Category: Research Source Type: clinical trials
Haploidentical Hematopoietic Stem Cell Transplantation With Early ATG and Low Dose Post-transplant Cyclophosphamide
Condition: Haploidentical Hematopoietic Stem Cell Transplantation Intervention: Drug: ATG-LDPTCy Sponsor: Samsung Medical Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 18, 2023 Category: Research Source Type: clinical trials
Safety and Efficacy Evaluation of Autologous CRISPR-Cas12b Edited Hematopoietic Stem Cells
Conditions: Thalassemia, Beta; Thalassemia Major Intervention: Biological: VGB-Ex01 Sponsors: Institute of Hematology& Blood Diseases Hospital, China; Shanghai Vitalgen BioPharma Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 18, 2023 Category: Research Source Type: clinical trials
Haploidentical Hematopoietic Stem Cell Transplantation With Early ATG and Low Dose Post-transplant Cyclophosphamide
Condition: Haploidentical Hematopoietic Stem Cell Transplantation Intervention: Drug: ATG-LDPTCy Sponsor: Samsung Medical Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 18, 2023 Category: Research Source Type: clinical trials
Safety and Efficacy Evaluation of Autologous CRISPR-Cas12b Edited Hematopoietic Stem Cells
Conditions: Thalassemia, Beta; Thalassemia Major Intervention: Biological: VGB-Ex01 Sponsors: Institute of Hematology& Blood Diseases Hospital, China; Shanghai Vitalgen BioPharma Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 18, 2023 Category: Research Source Type: clinical trials
Haploidentical Hematopoietic Stem Cell Transplantation With Early ATG and Low Dose Post-transplant Cyclophosphamide
Condition: Haploidentical Hematopoietic Stem Cell Transplantation Intervention: Drug: ATG-LDPTCy Sponsor: Samsung Medical Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 18, 2023 Category: Research Source Type: clinical trials
Safety and Efficacy Evaluation of Autologous CRISPR-Cas12b Edited Hematopoietic Stem Cells
Conditions: Thalassemia, Beta; Thalassemia Major Intervention: Biological: VGB-Ex01 Sponsors: Institute of Hematology& Blood Diseases Hospital, China; Shanghai Vitalgen BioPharma Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 18, 2023 Category: Research Source Type: clinical trials
Safety and Efficacy Evaluation of Autologous CRISPR-Cas12b Edited Hematopoietic Stem Cells
Conditions: Thalassemia, Beta; Thalassemia Major Intervention: Biological: VGB-Ex01 Sponsors: Institute of Hematology & Blood Diseases Hospital; Shanghai Vitalgen BioPharma Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 18, 2023 Category: Research Source Type: clinical trials
Haploidentical Hematopoietic Stem Cell Transplantation With Early ATG and Low Dose Post-transplant Cyclophosphamide
Condition: Haploidentical Hematopoietic Stem Cell Transplantation Intervention: Drug: ATG-LDPTCy Sponsor: Samsung Medical Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 18, 2023 Category: Research Source Type: clinical trials
Cardiac Toxicity and Prognostic Value of New Echocardiographic Indicators in the Treatment of Primary Multiple Myeloma
Condition: Multiple Myeloma Intervention: Other: Chemotherapy and/or autologous hematopoietic stem cell transplantation Sponsor: Qilu Hospital of Shandong University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
